Altria GroupFDA streamlining premarket review would speed authorization of Altria's flavored vapes and NJOY nicotine pouches
The Trump administration is preparing a major regulatory shift to accelerate market authorization for smoke-free nicotine products, according to reporting by The Wall Street Journal. The Food and Drug Administration is expected to announce changes in coming days that ease the requirements of its 2021 premarket review framework, establishing a streamlined pathway for alternative nicotine delivery systems, particularly flavored vapes and nicotine pouches. The overhaul aims to simplify scientific study standards and shorten review times for non-combustible alternatives, which under existing rules face years of regulatory backlog. A streamlined process would provide a substantial operational tailwind for major tobacco operators including Altria Group, Philip Morris International and British American Tobacco, and Altria's NJOY vape division recently joined other industry players in suing the FDA over regulatory delays. Administration officials view the proposed rules as a way to displace illicit, unregulated products dominating the domestic marketplace, but the shift faces pushback from public health advocates and bipartisan lawmakers who argue that expanding flavored product authorizations risks increasing youth adoption rates.
Altria GroupFDA streamlining premarket review would speed authorization of Altria's flavored vapes and NJOY nicotine pouches
British American Tobacco PLCStreamlined FDA review of flavored vapes and nicotine pouches is a regulatory tailwind for British American Tobacco
Philip Morris International IncFaster FDA authorization pathway for smoke-free nicotine products benefits Philip Morris International's alternatives portfolio
Bill Com Holdings Inc